evipedia.ai
← Back

Thymosin Alpha-1 for Health & Longevity

Evidence Review created on 10/29/2026 using AI4L / Opus 5.5

Also known as: Thymosin α1, Tα1, Ta1, TA1, Thymalfasin, Zadaxin

Motivation

Thymosin alpha-1 (thymalfasin) is a small protein fragment, 28 amino acids long, that the thymus releases into the blood. The thymus is the gland behind the breastbone where infection-fighting white blood cells mature. A lab-made version is sold as a prescription injection in dozens of countries. It draws interest from people focused on longevity because the thymus shrinks steadily from early adulthood, and the weakening of the immune system is one of the most consistent features of growing older.

It was first isolated from calf thymus in the 1970s. It has since been studied as an add-on treatment for chronic viral hepatitis and severe infections, and as a way to strengthen weak responses to influenza vaccination in older adults. In the United States it is not an approved drug, yet it circulates through longevity clinics and research-chemical sellers, and regulators have raised questions about the quality of those products.

This review examines what human trials show about its benefits and harms, how that evidence applies to healthy adults hoping to slow immune aging, and what is known about dosing, sourcing, monitoring and legal status.

Benefits - Risks - Protocol - Conclusion

The items below give a high-level overview of thymosin alpha-1, its proposed role in immune aging, and the debate over access to it.

  • How Many Needless Deaths? - William Faloon

    An advocacy essay arguing that the peptide counters age-related thymic decline and that American patients have been denied access; useful for the longevity rationale, though openly promotional in tone.

  • Peptides: The Science, Uses & Safety – Dr. Abud Bakri - Andrew Huberman

    A physician interview with a dedicated segment on age-related thymus shrinkage and thymosin alpha-1’s role in immune function, set within a broader discussion of peptide sourcing and the animal-to-human evidence gap.

  • Aging and Thymosin Alpha-1 - Simonova et al., 2025

    A 2025 narrative review linking thymic shrinkage to immune aging and summarizing laboratory, animal and limited human data on the peptide’s effects in older organisms.

  • Thymosin alpha 1: A comprehensive review of the literature - Dominari et al., 2020

    A broad narrative review of the peptide’s history, mechanisms and clinical uses across hepatitis, cancer, sepsis (life-threatening organ failure from infection) and immune deficiency; a useful single starting reference.

  • Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries - Ershler et al., 2007

    Written by investigators behind the older-adult vaccine trials, it summarizes the rationale and results for using the peptide to strengthen influenza vaccine responses in later life.

No dedicated content was found from Peter Attia (his site’s two matching articles are paywalled and their visible text concerns thymosin beta-4), Rhonda Patrick, Chris Kresser or Lifespan.io; their site searches returned nothing that discusses thymosin alpha-1 by name.

Grokipedia

  • Thymosin alpha 1

    An AI-written encyclopedia overview of the peptide’s discovery, immune-modulating actions and clinical uses; helpful for orientation, but it does not replace the primary trials cited in this review.

Examine

No Examine article on thymosin alpha-1 exists. Thymosin alpha-1 is a prescription injectable drug in the countries where it is approved, and Examine.com does not typically cover prescription medications or injectable peptides.

ConsumerLab

No ConsumerLab article on thymosin alpha-1 exists; the site’s search returns only passing mentions in regulatory warning notices about COVID-19 marketing claims. Thymosin alpha-1 is a prescription injectable drug abroad, and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

The following systematic reviews and meta-analyses cover the main clinical uses of thymosin alpha-1, including its adverse-event profile.

Harms are represented through the adverse-event analyses above. No systematic review or meta-analysis has examined thymosin alpha-1 in healthy or older adults for immune-aging or longevity outcomes.

Mechanism of Action

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide cut from a larger precursor protein, prothymosin alpha; its acetylated (chemically capped) starting end helps it anchor to cell membranes (Simonova 2025). No dedicated receptor has been identified. A review by authors employed by SciClone Pharmaceuticals, maker of the branded drug Zadaxin, describes action mainly through toll-like receptors (TLRs, sensors that detect microbial signals) on dendritic cells (the immune system’s antigen-presenting “scouts”) (King 2016).

  • Immune activation: Per a review, TLR9 signaling through MyD88 (a relay protein) matures dendritic cells, raises interleukin-12 (a T-cell-activating signal) and interferon-alpha (an antiviral protein), and supports production of new T cells (white blood cells that direct and carry out targeted immune attacks) (Simonova 2025).
  • Immune restraint: In mouse dendritic-cell studies, Tα1 also induces indoleamine 2,3-dioxygenase (IDO, an enzyme whose tryptophan breakdown dampens immune responses), interleukin-10 (an anti-inflammatory signal) and regulatory T cells (Tregs, cells that prevent excessive inflammation) (Romani 2006).

These opposing actions support two readings. Proponents describe a “balancing” immune modulator; skeptics note that no human study shows it restores thymic function in healthy older adults.

  • Pharmacology: A drug monograph reports that after subcutaneous (under-the-skin) injection, serum levels peak within 2 hours and the half-life is about 2 hours (Ancell 2001).
  • Distribution and elimination: In mice, it concentrates in thymus, spleen, lungs and kidneys and is rapidly excreted in urine (Badamchian 1997). Breakdown by proteases (protein-cutting enzymes), not cytochrome P450 (the liver’s main drug-metabolizing enzymes), is inferred from its structure.

Historical Context & Evolution

Thymosin alpha-1 grew out of work by Allan Goldstein and Abraham White, whose calf-thymus extract (thymosin fraction 5) restored immunity in thymus-deficient animals. Tα1 was the first active peptide sequenced from it (Goldstein 1977). It was meant to rebuild immunity in immune-deficient and chemotherapy-weakened patients.

  • Clinical development: Trials in the 1980s–1990s covered lung cancer, melanoma (skin cancer) and hepatitis B and C (Zadaxin label (RxList)); a review summarizes older-adult influenza-vaccine trials (Ershler 2007). Synthetic thymalfasin (Zadaxin) became approved in about 35 countries, chiefly for viral hepatitis (Simonova 2025); in Italy it is authorised to enhance influenza vaccine responses (EMA (European Medicines Agency) orphan designation EU/3/02/110). It was in U.S. Phase III (large late-stage) trials in 2001 (Ancell 2001); its U.S. orphan-drug designation (a rare-disease status) is not a marketing approval (EMA orphan designation EU/3/02/110).
  • Longevity interest: Because the thymus shrinks with age, Life Extension advocated the peptide for reversing immune aging in 1981 (Life Extension 1981 reprint). COVID-19 and U.S. peptide clinics renewed attention.
  • Regulation: The FDA (Food and Drug Administration) reviewed it for compounding at a December 2024 advisory meeting (FDA advisory committee meeting page).
  • Evolving evidence: Small early trials were mostly positive; later large double-blind trials (neither patients nor investigators know who receives the drug) in sepsis (Wu 2025), pancreatitis (pancreas inflammation) (Ke 2022) and hepatitis C (Ciancio 2012) found no main-outcome effect. Advocates counter in a narrative review that over 11,000 subjects show safety and efficacy (Dinetz 2024). Neither reading is final.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the replicated human trials are small or open-label (unblinded) studies in disease populations, and the largest double-blind trials in sepsis (Wu 2025), pancreatitis (Ke 2022) and hepatitis C (Ciancio 2012) found no effect on their primary outcomes.

Medium 🟩 🟩

Stronger Vaccine Responses in Older Adults

In a double-blind trial of 90 men aged 65–99, twice-weekly Tα1 started at influenza vaccination raised the share achieving a fourfold antibody rise, with the largest gain above age 77 (Gravenstein 1989). A pilot trial in hemodialysis (machine blood filtering for kidney failure) patients found higher antibody responses to a pandemic influenza vaccine (Carraro 2012), and Italy authorises the peptide for this use (EMA orphan designation EU/3/02/110). The group figures come from a summary co-authored by SciClone’s chief scientific officer (Tuthill 2010). This benefit is closest to healthy aging.

Magnitude: A fourfold antibody rise occurred in 69% (31/45) with Tα1 vs 52% (21/40) with placebo; in a separate 330-person trial of older adults, influenza occurred in 5.5% after 4 weeks of Tα1 vs 19% with placebo, as reported by Tuthill 2010.

Chronic Hepatitis B Control ⚠️ Conflicted

A 2026 Cochrane review pooled 10 randomized trials (1,349 adults) of Tα1 alone or added to antivirals; it found lower all-cause mortality and fewer serious adverse events, but rated certainty very low, and four trials were industry-funded (Naing 2026). The largest trial (690 adults with cirrhosis, a scarred liver) found no difference in liver decompensation (loss of liver function), liver cancer or death when Tα1 was added to the antiviral entecavir (Wu 2018). It applies only to HBV infection. Net: a possible but unproven survival benefit.

Magnitude: All-cause mortality risk ratio (RR, risk in the treated group divided by risk in the control group) 0.53 (95% confidence interval [CI, the range likely to contain the true value] 0.29–0.96; 3 trials, 907 participants) vs control (Naing 2026).

Lung Function in Chronic Lung Disease Flare-Ups

A meta-analysis of 39 randomized trials (3,329 patients), all from Chinese centres that it does not separate by research group, found that adding Tα1 to routine care of chronic obstructive pulmonary disease (COPD) flare-ups improved lung function and blood oxygen and shortened hospital stay (Cao 2024). The authors call for higher-quality trials, and none has been run outside China. It applies to people with COPD, not healthy adults.

Magnitude: Hospital stay 5.39 days shorter (95% CI 2.97–7.82) and forced expiratory volume in 1 second (FEV1, air exhaled in the first second) mean difference 0.29 (95% CI 0.26–0.32) vs routine care alone (Cao 2024).

Cancer Treatment Add-On ⚠️ Conflicted

Added to chemotherapy in 488 patients with metastatic melanoma (skin cancer that has spread), Tα1 increased tumor responses, the trial’s primary endpoint (Maio 2010). A meta-analysis of 20 small Chinese randomized trials in gastric cancer found higher response rates with Tα1 plus chemotherapy (moderate certainty in the full text; the abstract calls overall certainty low), without survival data (Wang 2026). For survival, Maio found only a non-significant trend, as did a Cochrane review (Wolf 2011). Net: tumor responses improve, but a survival benefit is unproven.

Magnitude: Objective response RR 1.39 (95% CI 1.26–1.53) vs chemotherapy alone across 16 trials (Wang 2026); median overall survival 9.4 months with Tα1 vs 6.6 months in the control group (hazard ratio [HR, relative rate of death over time] 0.80, 95% CI 0.63–1.02; P [probability the result arose by chance] = .08) (Maio 2010); pooled survival RR 1.21 (95% CI 0.94–1.56) for Tα1 vs control (Wolf 2011).

Low 🟩

Sepsis Survival ⚠️ Conflicted

A single-blind trial suggested lower 28-day mortality in sepsis (life-threatening organ failure from infection) (Wu 2013), but the larger double-blind TESTS trial found none (Wu 2025). Pooled benefit vanishes in high-quality trials (Gu 2025). Net: no proven survival benefit.

Magnitude: 28-day mortality 23.4% with Tα1 vs 24.1% with placebo (hazard ratio [HR, relative rate of death over time] 0.97, 95% CI 0.76–1.24, per the full text; the PubMed abstract gives 0.99, 0.77–1.27) (Wu 2025); pooled odds ratio (OR, relative odds) 0.73 (95% CI 0.59–0.90) across 11 trials, but 0.82 (0.65–1.03) in high-quality trials (Gu 2025).

COVID-19 Outcomes ⚠️ Conflicted

Meta-analyses of mostly observational (non-randomized) hospital data disagree: one found no mortality effect (Shang 2023), another lower mortality in moderate-to-critical illness (Soeroto 2023). A randomized prevention trial in 189 dialysis patients found similar infection counts (NCT04428008). Net: no reliable benefit.

Magnitude: Mortality RR 1.03 (95% CI 0.60–1.75) across 9 studies (Shang 2023) vs RR 0.59 (95% CI 0.37–0.93) across 8 studies (Soeroto 2023); COVID-19 infection in 5 of 91 with Tα1 vs 7 of 98 with standard care (NCT04428008).

Chronic Hepatitis C Response ⚠️ Conflicted

A review of small 1990s trials reported better responses when Tα1 was added to interferon (Ancell 2001). A placebo-controlled trial in 552 prior non-responders adding it to peginterferon and ribavirin (an antiviral drug) found no gain in cure rate (Ciancio 2012). Net: no benefit shown in prior non-responders.

Magnitude: Sustained virologic response (lasting viral clearance after treatment ends) 12.7% with Tα1 vs 10.5% with placebo (P = 0.407) (Ciancio 2012).

Infectious Complications of Severe Acute Pancreatitis ⚠️ Conflicted

Pooled Chinese trials reported fewer infections outside the pancreas in severe acute pancreatitis (pancreas inflammation) (Tian 2025). The double-blind TRACE trial (508 patients) found no reduction in infected pancreatic necrosis (infected dead pancreatic tissue) (Ke 2022). Net: unconfirmed.

Magnitude: Infections outside the pancreas RR 0.56 (95% CI 0.40–0.78) vs control across 3 trials (Tian 2025); infected necrosis 15.7% with Tα1 vs 18.1% with placebo (difference −2.4%, 95% CI −7.4% to 5.1%) (Ke 2022).

Speculative 🟨

Restoring Thymic Output and Reversing Immune Aging

In a 20-patient human immunodeficiency virus (HIV) trial, Tα1 raised TRECs (markers of newly made T cells) without changing CD4 (helper T-cell) counts (Chadwick 2003). No human study measured thymic renewal in healthy older adults.

Dampening Inflammaging and Oxidative Stress

A review of cell and animal studies reports Tα1 lowers inflammatory signals and oxidative damage (cell injury from reactive oxygen), framed as countering inflammaging (chronic low-grade inflammation of aging) (Simonova 2025). Mechanistic basis only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No genetic variant has been studied as a modifier of response to Tα1; no pharmacogenetic data exist.
  • Baseline lymphocyte count: In a TRACE post-hoc analysis (one not planned in advance), Tα1 significantly reduced infected necrosis only in the subgroup with lymphocytes ≥0.8 × 10⁹/L (Ke 2023), suggesting a minimum immune reserve is needed for a response.
  • Sex: The key vaccine trial enrolled only men (Gravenstein 1989). A COVID-19 meta-analysis linked mortality benefit to study groups with ≤40% women (Shang 2023), a confounded finding (distorted by other study differences).
  • Pre-existing conditions: Signals of benefit cluster in weakened immune states (dialysis, chronic hepatitis B, cancer); in sepsis, a diabetes subgroup fared better (Wu 2025). Healthy adults with intact immunity may gain less.
  • Age: Vaccine gains were largest above age 77 (Gravenstein 1989), and COVID-19 benefit appeared only in groups averaging over 60 (Shang 2023), consistent with greater room for improvement in older immune systems.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: placebo-controlled trials from several research groups report no excess of any specific adverse event, so no harm is replicated in controlled data.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial has shown a statistically significant excess of a specific harm across its whole population; the signals below rest on uncontrolled reports, a subgroup analysis, or regulator concerns without human outcome data.

Low 🟥

Injection-Site Reactions

Local irritation at the injection site is the most frequently described reaction across trials, generally mild (Ancell 2001). Repeated self-injection over months increases cumulative exposure to this and to injection-related infection.

Magnitude: Not quantified in available studies. The source review describes local irritation without rates for treatment and comparison groups, so no comparison-group rate is available.

Joint Pain, Hand Swelling and Rash

The Zadaxin label lists rare erythema (skin redness), transient muscle atrophy (muscle wasting), polyarthralgia (pain in several joints) with hand edema (swelling), and rash (Zadaxin label (RxList)). A pharmacist monograph describes the drug as well tolerated (Ancell 2001). No comparison-group rates are reported.

Magnitude: Drug-related adverse events of any type in under 1% of more than 2,000 treated individuals (no control group; the source gives no comparison-group rate) (Zadaxin label (RxList)).

Serious Adverse Events ⚠️ Conflicted

As an immune stimulant, Tα1 raises concern about serious events; in a liver-tumor chemoembolization (chemotherapy delivered through the tumor’s artery) trial, 7 of 14 treated and 7 of 11 control patients had one (Gish 2009). Controlled data show no excess (Naing 2026; Wu 2025). Net: no excess risk detected.

Magnitude: Serious adverse events RR 0.72 (95% CI 0.53–0.99) vs control across 5 trials (Naing 2026); 7 of 14 with Tα1 plus chemoembolization vs 7 of 11 with chemoembolization alone (Gish 2009).

Liver Enzyme Flares in Hepatitis B

In a 316-patient Japanese trial, most drug reactions were fluctuations in liver enzymes, which investigators attributed to immune attack on infected liver cells (Iino 2005). The trial compared two doses without a placebo group. Relevant to people with hepatitis B.

Magnitude: Not quantified in available studies. The trial reports liver-enzyme fluctuation as the most common reaction without rates, and it had no placebo group.

Possible Harm in Younger Adults With Sepsis

In the TESTS trial, a prespecified subgroup analysis suggested higher 28-day mortality with Tα1 in adults under 60 and a possible benefit at 60 or older (Wu 2025). Subgroup findings are hypothesis-generating; no mechanism is established.

Magnitude: Death HR 1.67 (95% CI 1.04–2.67) with Tα1 vs placebo in adults under 60, and HR 0.81 (95% CI 0.61–1.09) at 60 or older (P for interaction, testing whether the effect differs by age, = 0.01) (Wu 2025).

Speculative 🟨

Impurities and Immunogenicity of Compounded or Gray-Market Product

The FDA states compounded Tα1 may pose significant immunogenicity (antibody-formation) risk and peptide-impurity problems, with inadequate safety information (FDA safety-risks page). No human outcome data exist.

Autoimmune Flares

Stimulating dendritic cells and T cells could theoretically worsen autoimmune disease, although Tα1 also promotes regulatory T cells (Romani 2006). The concern is mechanistic; no controlled data exist.

Weakened Immunosuppression After Transplant

Immune activation could theoretically counteract anti-rejection drugs in organ or stem-cell transplant recipients. The concern is mechanistic; no controlled data or isolated reports in transplant recipients were identified.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic studies exist. Because Tα1 is a peptide cleared by protein breakdown and urine, variants in CYP2D6 or CYP3A4 (liver enzymes that metabolize many drugs) are not expected to alter exposure; this is inferred, not studied.
  • Baseline biomarkers: Elevated liver enzymes or detectable HBV DNA (viral genetic material in blood) signal active hepatitis B, where enzyme flares occur (Iino 2005); markers of active autoimmunity raise the theoretical flare concern.
  • Sex: No sex-specific adverse-event differences have been reported. Safety in pregnancy and breastfeeding has not been studied, so women who could become pregnant face unknown reproductive risk.
  • Pre-existing conditions: Autoimmune disease, organ or stem-cell transplantation, and active cancer treated with immune checkpoint inhibitors (cancer drugs that release the brakes on T cells) carry theoretical risks of unwanted immune activation; chronic hepatitis B carries a documented enzyme-flare signal.
  • Age: Men aged 65–99 tolerated vaccine-adjunct courses without observed toxicity (Gravenstein 1989); the only age-linked harm signal is in sepsis patients under 60 (Wu 2025).

Key Interactions & Contraindications

Documented interactions:

  • Interferon alfa (peginterferon, interferon alfa-2b): Combined in melanoma and hepatitis C trials; no interaction found, with no added toxicity (Maio 2010; Ciancio 2012). Standard interferon monitoring applies as usual.
  • Chemotherapy (dacarbazine, a chemotherapy drug that damages cancer-cell DNA): Adding Tα1 to dacarbazine and interferon caused no additional toxicity in 488 melanoma patients; no interaction found (Maio 2010).
  • Hepatitis B antivirals (entecavir): Combination was well tolerated over 52 weeks; no interaction found, and pooled adverse events were lower with the combination (Wu 2018; Peng 2020). Hepatitis B monitoring continues as usual.
  • Influenza vaccines: Given alongside vaccination, Tα1 increased antibody responses (an intended, favorable interaction) without vaccine-related safety signals (Gravenstein 1989; Carraro 2012). Trials began the course at vaccination.
  • Immunosuppressants (drugs that dampen immunity: tacrolimus, cyclosporine, mycophenolate, prednisone): The Zadaxin label considers Tα1 contraindicated during deliberate immunosuppression (e.g., transplant) unless benefits clearly outweigh risks, as opposing effects risk rejection (Zadaxin label (RxList)). Mitigation: avoided after transplant; otherwise coordinated with the prescriber.
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab): The Zadaxin label advises caution with other immunomodulating drugs; additive T-cell activation could raise immune-related adverse events (immune attack on healthy organs) (Zadaxin label (RxList)). Mitigation: confined to oncology care with immune-toxicity monitoring.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Over-the-counter fever and pain relievers (acetaminophen, ibuprofen, naproxen): No effect on Tα1 clearance is expected because it is not liver-enzyme metabolized, but these drugs can mask fever from injection-site infection. Mitigation: injection-site checks while fever is masked.
  • Immune-stimulating supplements (echinacea, beta-glucans, elderberry): Additive immune stimulation could amplify inflammatory symptoms or autoimmune activity. Mitigation: adding one agent at a time while tracking symptoms.
  • Other immune-active peptides (thymosin beta-4/TB-500, thymulin): Overlapping thymic and immune signaling may add effects and stack product-quality risks. Mitigation: not starting several unregulated peptides at once.

Populations who should avoid Thymosin Alpha-1:

  • Organ or stem-cell transplant recipients on immunosuppression: The Zadaxin label considers Tα1 contraindicated in deliberately immunosuppressed patients, such as organ transplant recipients, unless benefits clearly outweigh risks (Zadaxin label (RxList)).
  • Adults under 60 with sepsis: Subgroup analysis showed higher 28-day mortality (HR 1.67) (Wu 2025).
  • Pregnancy and breastfeeding: The Zadaxin label reserves use in pregnancy for when benefits clearly outweigh risks and advises caution in breastfeeding, as human safety data are lacking (Zadaxin label (RxList)).
  • Active or poorly controlled autoimmune disease: Inferred from dendritic-cell and T-cell stimulation; no human data.
  • Known hypersensitivity to thymosin alpha-1 or product excipients: Contraindicated per the Zadaxin label (Zadaxin label (RxList)).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pharmaceutical-grade sourcing: Using a regulated product (Zadaxin where approved) rather than research-chemical vials mitigates the FDA-flagged impurity and immunogenicity risk (FDA safety-risks page).
  • Aseptic injection technique: Rotating subcutaneous sites, using sterile single-use needles and using each vial immediately after reconstitution, as the label directs (Zadaxin label (RxList)), reduce injection-site reactions and infection.
  • Hepatitis B screening and oversight: Baseline hepatitis B surface antigen and 4-week ALT (alanine aminotransferase, a liver enzyme) testing catches flares; the label expects transient rises above twice baseline, continuing use unless liver failure develops (Zadaxin label (RxList)).
  • Autoimmune screening: Excluding active autoimmune disease and tracking new joint, skin or thyroid symptoms mitigates theoretical autoimmune flares; use is paused at symptom onset.
  • Transplant and checkpoint-inhibitor exclusion: Not using Tα1 alongside anti-rejection drugs, and using it with checkpoint inhibitors only in supervised oncology trials, mitigates rejection and immune-related toxicity.
  • Time-limited courses: Restricting use to defined courses (for example, 4–8 weeks around vaccination, matching trial durations) limits cumulative exposure to unknown long-term effects (Gravenstein 1989).

Therapeutic Protocol

Doses below are cited to their sources; other parameters without a citation (timing, cycling, course length, titration) reflect common practice.

  • Hepatitis B label regimen: 1.6 mg (about 900 µg/m² body surface area) subcutaneously twice weekly for 6–12 months (Ancell 2001).
  • Vaccine-adjunct regimen: 900 µg/m² subcutaneously twice weekly for eight doses, begun with influenza vaccination in men aged 65–99 (Gravenstein 1989). An ongoing trial tests a single 4.8 mg dose before a COVID-19 booster (NCT06821100).
  • Critical-illness regimen: 1.6 mg every 12 hours for 7 days in sepsis (Wu 2025); this intensive dosing has no counterpart in healthy use.
  • Healthy-aging use: No regimen has been tested in healthy adults; peptide clinics borrow the 1.6 mg twice-weekly label dose (Ancell 2001), either as continuous multi-month courses or as vaccine-timed pulses, with neither approach shown superior.
  • Who popularized it: Allan Goldstein discovered it, SciClone Pharmaceuticals commercialized Zadaxin, Life Extension championed longevity use, and peptide physicians such as Craig Koniver discussed it (Huberman Lab Koniver episode).
  • Time of day: No study compared dosing times; trials did not specify one. Consistent timing, often morning, is common practice.
  • Half-life: About 2 hours, with serum levels back to baseline within 24 hours (Ancell 2001); twice-weekly dosing relies on immune effects outlasting blood levels.
  • Single vs split dosing: Chronic regimens use one injection per dosing day; split every-12-hour dosing appears only in critical-illness trials (Wu 2025).
  • Genetic polymorphisms: No variants are known to influence dose; no pharmacogenetic adjustment exists.
  • Sex: No sex-specific dosing exists; body-surface dosing in the vaccine trial scaled dose to body size (Gravenstein 1989).
  • Age: Standard doses were used up to age 99; in the vaccine trial, the antibody gain was largest above age 77 (Gravenstein 1989).
  • Baseline biomarkers: In pancreatitis, a significant benefit appeared only with lymphocyte counts ≥0.8 × 10⁹/L (Ke 2023); patients with lower counts showed no significant benefit.
  • Pre-existing conditions: Hepatitis B trials gave Tα1 under hepatologist (liver specialist) care alongside antivirals; autoimmune disease, transplantation and checkpoint-inhibitor therapy carry the theoretical immune-activation risks described above.

Discontinuation & Cycling

  • Short-term vs lifelong: Every trial regimen was time-limited, from 7 days to 12 months; no continuous long-term use has been studied, so the intervention is short-term by evidence.
  • Withdrawal effects: None reported; Tα1 is not habit-forming, and immune effects wane over days to weeks after stopping.
  • Tapering: Not required; trials stopped without tapering. In hepatitis B, the antiviral drug, not Tα1, is what must not be stopped abruptly.
  • Cycling: Common practice uses courses timed to vaccination or seasonal infection periods. No study shows tolerance develops or that cycling preserves efficacy.
  • Restarting: Repeat courses (for example, with each annual vaccination) follow common practice; antibody formation against the peptide over repeated courses has not been studied.

Sourcing and Quality

  • Pharmaceutical product: Zadaxin (thymalfasin, SciClone Pharmaceuticals) is the reference product, a lyophilized (freeze-dried) 1.6 mg vial approved in about 35 countries (Simonova 2025).
  • U.S. compounding status: The FDA lists Tα1 among nominations withdrawn from category 2, citing immunogenicity and impurity concerns (FDA safety-risks page); in December 2024 an FDA advisory committee reviewed it for inclusion on the pharmacy-compounding list (FDA advisory committee meeting page).
  • Research-chemical vendors: Vials sold “for research use only” carry no pharmaceutical quality control; purity, sterility, endotoxin (bacterial toxin) content and dose accuracy are unverified.
  • What to look for: A batch-specific certificate of analysis with HPLC (high-performance liquid chromatography) purity, mass-spectrometry identity confirming the acetylated 28-amino-acid sequence, and sterility and endotoxin tests from an independent laboratory.
  • Storage: Lyophilized vials are kept refrigerated and reconstituted with sterile diluent immediately before use; reconstituted solution is used promptly (common practice).
  • Brands and pharmacies: Zadaxin is the only pharmaceutical brand with trial data; supplement-style certification programs do not cover injectable peptides.

Practical Considerations

  • Time to effect: CD4 cells rose within 5 days in hospitalized COVID-19 patients on low-flow oxygen (Shehadeh 2023); vaccine antibody gains appeared within 3–6 weeks (Gravenstein 1989); hepatitis B responses take 6–12 months.
  • Common pitfalls: Relying on unverified research-grade vials, expecting a felt energy effect, using Tα1 as a substitute for vaccination, and starting during an autoimmune flare.
  • Regulatory status: No U.S. marketing approval; its U.S. orphan designation is not an authorisation (EMA orphan designation EU/3/02/110); reviewed at a December 2024 FDA advisory meeting (FDA advisory committee meeting page); U.S. access runs through compounding of uncertain status, import, or gray-market sellers.
  • Cost and accessibility: Zadaxin is not sold in the United States, so legal access is difficult; ongoing twice-weekly injections over months add cost and inconvenience.
  • Evidence provenance and funding: Much supportive data comes from manufacturer-linked authors or small single-country trials. Because the peptide is off-patent and no U.S. payer covers it, neither manufacturers nor insurers have an incentive to fund large trials in healthy older adults.

Interaction with Foundational Habits

  • Sleep: Direction: none known directly. Tα1 has not been reported to affect sleep. Because sleep loss weakens vaccine antibody responses, protecting sleep in the days around vaccination plausibly complements vaccine-timed Tα1 courses (indirect, mechanistic).
  • Nutrition: Direction: indirect. Being injected, Tα1 has no food interactions. Adequate protein, zinc and vitamin D support T-cell function; deficiency may limit the immune response the peptide aims to strengthen, so correcting deficiencies before a course is common practice.
  • Exercise: Direction: none studied; possibly additive. Regular moderate exercise is independently associated with better immune function in older adults. Avoiding unusually exhaustive sessions in the days after vaccination is common practice; no trial tested exercise with Tα1.
  • Stress management: Direction: indirect, potentially counteracting. Chronic stress raises cortisol (the main stress hormone), which shrinks the thymus and suppresses T cells; a manufacturer-authored summary reports that Tα1 opposes glucocorticoid (steroid stress hormone)-induced death of thymocytes (immature T cells) in lab studies (Tuthill 2010). Stress reduction addresses the underlying driver.

Monitoring Protocol & Defining Success

Baseline testing before a first course documents immune status and screens out conditions where immune stimulation is unwanted: a complete blood count with differential for lymphocytes, a CD4/CD8 lymphocyte panel (helper and killer T-cell counts), liver enzymes, hepatitis B surface antigen, and, when the course is timed to a vaccine, a pre-vaccination antibody titer (antibody level). Autoimmune symptoms and current medications, especially immunosuppressants and checkpoint inhibitors, are reviewed at the same visit.

Ongoing monitoring follows this cadence: blood count and liver enzymes at 4 weeks, then every 3 months during continued use; the vaccine antibody titer 4–6 weeks after vaccination; and lymphocyte subsets 8–12 weeks after starting. Success is defined as a measurable rise in vaccine antibody titer or lymphocyte counts relative to the individual’s own baseline, together with fewer or shorter infections, and no liver-enzyme flare or new autoimmune symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Absolute lymphocyte count 1.0–4.8 × 10⁹/L (standard reference range) Expected to change; also predicts response Part of the CBC (complete blood count) with differential; no fasting needed. In pancreatitis, benefit was significant only with counts ≥0.8 × 10⁹/L (Ke 2023).
CD4+ T-cell count and CD4/CD8 ratio CD4+ 500–1,500 cells/µL (standard reference range) Expected to change CD4+ cells are helper T cells and CD8+ cells are killer T cells, measured by flow cytometry (laser-based cell counting). Morning draws reduce daily variation.
ALT 7–56 U/L (standard reference range) Safety check: a flare stops or changes use ALT (alanine aminotransferase) is a liver-injury enzyme, usually paired with AST (aspartate aminotransferase). Flares occurred in hepatitis B (Iino 2005); heavy exercise in the 48 hours before testing can raise values.
Hepatitis B surface antigen Negative (standard reference range) Safety check: a positive result changes use HBsAg (hepatitis B surface antigen) marks active HBV infection; hepatitis B trials gave Tα1 under specialist liver care alongside antivirals.
Vaccine-specific antibody titer No established target; track the rise from the individual’s own pre-vaccination titer Expected to change Measured 4–6 weeks after vaccination using the same laboratory and assay as baseline.

Qualitative markers:

  • Frequency and duration of colds, influenza-like illnesses and other infections
  • Recovery time after infections or vaccinations
  • Injection-site redness, swelling or pain
  • New joint pain, rashes or thyroid-related symptoms that could signal autoimmune activation
  • Energy levels and general sense of resilience during infection seasons

Emerging Research

  • Vaccine boosting in adults 65+: A randomized, open-label (unblinded) Phase 1 (early safety) trial (NCT06821100), 75 participants, testing Tα1 before COVID-19 boosters; primary endpoint adverse events, secondary antibody and T-cell responses; estimated completion December 2026. A positive result would reinforce the Medium vaccine benefit; a null result would weaken it.
  • Adjuvant colorectal cancer therapy: A Phase 3 randomized trial (NCT05086614) of 2,500 patients, primary endpoint 3-year disease-free survival (time without cancer recurrence), completion 2027. A positive result would provide the first large trial showing fewer cancer recurrences; a null result would extend the pattern of null large trials.
  • Melanoma in older adults: A single-arm (no comparison group) Phase 2 trial (NCT07644897), 55 patients, adding Tα1 to anti-PD-1 antibody (releases the PD-1 brake on T cells); primary endpoint objective response rate (share with tumor shrinkage). A positive result would support combined use; a null result or excess immune toxicity would heighten interaction concerns.
  • Sepsis immune recovery: A 60-patient randomized trial (NCT07866118) measuring monocyte HLA-DR (an immune-readiness marker) at day 7. A positive result would confirm biological activity; a null result would weaken the immune-restoration rationale.
  • Completed: dialysis COVID-19 prevention: Completed January 2023 with results posted (NCT04428008): infections 5 of 91 vs 7 of 98, deaths 3 vs 7. These results are cited in the COVID-19 benefit item.
  • Responder selection: Subgroup heterogeneity in sepsis (Gu 2025) and the lymphocyte threshold (Ke 2023) suggest stratified trials could identify true responders, strengthening the case; they could equally confirm minimal effects.
  • Null large trials: The pattern of null double-blind trials (Wu 2025; Ke 2022) suggests early positive results may reflect small-study bias, weakening the case.
  • Thymic renewal in healthy aging: The only human thymic-output data come from HIV (Chadwick 2003); a trial measuring thymic output or immune-aging clocks in healthy older adults would directly test the longevity premise.
  • Long-acting formulations: Engineered versions with extended half-lives (Binder 2020) could reduce injection frequency if human trials follow.

Conclusion

Thymosin alpha-1 is a natural thymus hormone, sold as a prescription injection in many countries but not approved in the United States, that pushes the immune system’s front-line cells and infection-fighting white blood cells toward a more active yet regulated state. Its appeal for longevity rests on a simple idea: the thymus shrinks with age, so replacing one of its signals might slow immune aging.

The human evidence does not yet test that idea directly. The most relevant findings come from older adults and people on dialysis, where the peptide appeared to strengthen responses to influenza vaccination, and from hepatitis B, where pooled trials hint at better survival with very low confidence. In severe blood infections, severe pancreas inflammation and hepatitis C, early positive results were not confirmed by larger, better-controlled trials; in COVID-19 and cancer, results remain mixed. No study has measured thymus renewal, immune aging or lifespan in healthy people.

Safety in the trials looks largely reassuring: overall harms matched placebo, apart from a hint of more deaths among younger patients with severe blood infections. The larger uncertainties are the quality of products sold outside pharmacies, which U.S. regulators flagged, and theoretical concerns for people with autoimmune disease or organ transplants.

Much supportive research comes from the manufacturer or its collaborators, and many trials are small and single-country. For health-focused adults, it is a plausible, low-harm immune signal whose clearest benefit is vaccine support in later life, while its broader promise of immune renewal remains unproven.

Top - Benefits - Risks - Protocol